319 related articles for article (PubMed ID: 33927214)
21. Protection of Iron-Induced Oxidative Damage in Neuroblastoma (SH-SY5Y) Cells by Combination of 1-(N-Acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one and Green Tea Extract.
Chansiw N; Kulprachakarn K; Paradee N; Prommaban A; Srichairatanakool S
Bioinorg Chem Appl; 2021; 2021():5539666. PubMed ID: 33986790
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol against 6-OHDA-induced damage of PC12 cells via PI3K/Akt.
Huang N; Huang J; Zhang Y; Chen M; Shi J; Jin F
Transl Neurosci; 2021 Jan; 12(1):138-144. PubMed ID: 33976931
[TBL] [Abstract][Full Text] [Related]
23. Prodromal sensory neuropathy in Pink1
Valek L; Tran B; Wilken-Schmitz A; Trautmann S; Heidler J; Schmid T; Brüne B; Thomas D; Deller T; Geisslinger G; Auburger G; Tegeder I
Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1060-1079. PubMed ID: 33974284
[TBL] [Abstract][Full Text] [Related]
24. [Mitochondrial therapy: a new strategy for treating mitochondrion-associated diseases].
Zhao Z; Fu A
Sheng Wu Gong Cheng Xue Bao; 2021 Apr; 37(4):1168-1177. PubMed ID: 33973433
[TBL] [Abstract][Full Text] [Related]
25. Tanshinone IIA: A phytochemical as a promising drug candidate for neurodegenerative diseases.
Subedi L; Gaire BP
Pharmacol Res; 2021 Jul; 169():105661. PubMed ID: 33971269
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies.
Su CF; Jiang L; Zhang XW; Iyaswamy A; Li M
Front Pharmacol; 2021; 12():644219. PubMed ID: 33967780
[TBL] [Abstract][Full Text] [Related]
27. Acteoside exerts neuroprotection effects in the model of Parkinson's disease via inducing autophagy: Network pharmacology and experimental study.
Aimaiti M; Wumaier A; Aisa Y; Zhang Y; Xirepu X; Aibaidula Y; Lei X; Chen Q; Feng X; Mi N
Eur J Pharmacol; 2021 Jul; 903():174136. PubMed ID: 33940032
[TBL] [Abstract][Full Text] [Related]
28. SIRT1 Deacetylates TET2 and Promotes Its Ubiquitination Degradation to Achieve Neuroprotection Against Parkinson's Disease.
Li X; Liu T; Wu TT; Feng Y; Peng SJ; Yin H; Wu YC
Front Neurol; 2021; 12():652882. PubMed ID: 33935952
[TBL] [Abstract][Full Text] [Related]
29. Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease.
Pérez-Lloret S; Cardinali DP
Front Pharmacol; 2021; 12():650597. PubMed ID: 33935759
[TBL] [Abstract][Full Text] [Related]
30. Hormonal replacement therapy in women with a history of internal genital organ malignancy.
Brzozowska M; Lewinski A
Prz Menopauzalny; 2021 Apr; 20(1):34-39. PubMed ID: 33935618
[TBL] [Abstract][Full Text] [Related]
31. Prolonged Treatment with Centella asiatica Improves Memory, Reduces Amyloid-β Pathology, and Activates NRF2-Regulated Antioxidant Response Pathway in 5xFAD Mice.
Zweig JA; Brandes MS; Brumbach BH; Caruso M; Wright KM; Quinn JF; Soumyanath A; Gray NE
J Alzheimers Dis; 2021; 81(4):1453-1468. PubMed ID: 33935097
[TBL] [Abstract][Full Text] [Related]
32. Implantation of human olfactory ecto-mesenchymal stem cells restores locomotion in a rat model of Parkinson's disease.
Farhadi M; Boroujeni ME; Kamrava SK; Bagher Z; Tehrani AM; Aghajanpour F; Ezi S; Soltani R; Khatmi A; Alizadeh R
J Chem Neuroanat; 2021 Jul; 114():101961. PubMed ID: 33933574
[TBL] [Abstract][Full Text] [Related]
33. Effect of aerobic exercise on functional capacity and quality of life in individuals with Parkinson's disease: A systematic review of randomized controlled trials.
de Oliveira MPB; Lobato DFM; Smaili SM; Carvalho C; Borges JBC
Arch Gerontol Geriatr; 2021; 95():104422. PubMed ID: 33932826
[TBL] [Abstract][Full Text] [Related]
34. BMI1 Drives Steroidogenesis Through Epigenetically Repressing the p38 MAPK Pathway.
Yu J; Wu Y; Li H; Zhou H; Shen C; Gao T; Lin M; Dai X; Ou J; Liu M; Huang X; Zheng B; Sun F
Front Cell Dev Biol; 2021; 9():665089. PubMed ID: 33928089
[TBL] [Abstract][Full Text] [Related]
35. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular dysautonomia and cognition in Parkinson's Disease - a possible relationship.
Kwaśniak-Butowska M; Dulski J; Pierzchlińska A; Białecka M; Wieczorek D; Sławek J
Neurol Neurochir Pol; 2021; 55(6):525-535. PubMed ID: 34037978
[TBL] [Abstract][Full Text] [Related]
37. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.
Schneider JS
Glycoconj J; 2022 Feb; 39(1):13-26. PubMed ID: 34037912
[TBL] [Abstract][Full Text] [Related]
38. Pain in Parkinson's disease and the role of the subthalamic nucleus.
Mostofi A; Morgante F; Edwards MJ; Brown P; Pereira EAC
Brain; 2021 Jun; 144(5):1342-1350. PubMed ID: 34037696
[TBL] [Abstract][Full Text] [Related]
39. [Update on the etiology and pathogenesis of muscle dystonia].
Bushueva OO; Antipenko EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(4):127-133. PubMed ID: 34037366
[TBL] [Abstract][Full Text] [Related]
40. [Amantadine in the treatment of Parkinson's disease. New opportunities in the context of COVID-19].
Katunina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(4):101-106. PubMed ID: 34037362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
